Dimensional Fund Advisors
KRYS icon

Dimensional Fund Advisors’s Krystal Biotech KRYS Stock Holding History

Dimensional Fund Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121M Sell
468,990
-23,978
-5% -$6.38M 0.03% 935
2025
Q4 		$122M Sell
492,968
-40,996
-8% -$8.63M 0.03% 928
2025
Q3 		$94.3M Buy
533,964
+28,075
+6% +$4.2M 0.02% 1120
2025
Q2 		$69.5M Sell
505,889
-28,030
-5% -$4.12M 0.02% 1292
2025
Q1 		$96.3M Sell
533,919
-54,680
-9% -$9.2M 0.02% 1007
2024
Q4 		$92.2M Sell
588,599
-11,662
-2% -$2.07M 0.02% 1098
2024
Q3 		$109M Buy
600,261
+19,809
+3% +$3.82M 0.03% 967
2024
Q2 		$107M Buy
580,452
+7,537
+1% +$1.27M 0.03% 911
2024
Q1 		$102M Buy
572,915
+22,109
+4% +$3.07M 0.03% 933
2023
Q4 		$68.3M Buy
550,806
+30,169
+6% +$3.35M 0.02% 1215
2023
Q3 		$60.4M Buy
520,637
+34,040
+7% +$4.15M 0.02% 1219
2023
Q2 		$57.1M Buy
486,597
+24,507
+5% +$2.5M 0.02% 1255
2023
Q1 		$37M Buy
462,090
+72,805
+19% +$5.72M 0.01% 1553
2022
Q4 		$30.8K Buy
389,285
+30,448
+8% +$2.26M 0.01% 1633
2022
Q3 		$25M Buy
358,837
+82,914
+30% +$5.99M 0.01% 1694
2022
Q2 		$18.1M Buy
275,923
+13,460
+5% +$837K 0.01% 1926
2022
Q1 		$17.5M Buy
262,463
+111,822
+74% +$6.98M 0.01% 2033
2021
Q4 		$10.5M Sell
150,641
-13,223
-8% -$770K ﹤0.01% 2289
2021
Q3 		$8.56M Sell
163,864
-49,848
-23% -$2.95M ﹤0.01% 2398
2021
Q2 		$14.5M Buy
213,712
+68,380
+47% +$4.77M ﹤0.01% 2195
2021
Q1 		$11.2M Buy
145,332
+76,988
+113% +$5.6M ﹤0.01% 2279
2020
Q4 		$4.1M Buy
68,344
+21,390
+46% +$1.07M ﹤0.01% 2594
2020
Q3 		$2.02M Buy
46,954
+11,096
+31% +$482K ﹤0.01% 2741
2020
Q2 		$1.49M Buy
+35,858
New +$1.73M ﹤0.01% 2840
2019
Q4 		– Sell
-14,270
Closed -$496K – 3395
2019
Q3 		$496K Buy
+14,270
New +$638K ﹤0.01% 3138

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors's KRYS Position: Q1 2026 in Review

Dimensional Fund Advisors reduced its Krystal Biotech (KRYS) stake by 4.9% in Q1 2026, selling an estimated $6.38M and leaving 468,990 shares worth $121M. The position accounts for 0.03% of the portfolio, ranked #935.

Dimensional Fund Advisors first reported a position in KRYS in Q3 2019 and has held it in 25 quarters since. The position peaked at $122M in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Dimensional Fund Advisors held 468,990 shares of Krystal Biotech worth $121M as of Q1 2026.
  • Dimensional Fund Advisors sold 23,978 Krystal Biotech shares in Q1 2026, an estimated $6.38M.
  • Krystal Biotech made up 0.03% of Dimensional Fund Advisors's portfolio in Q1 2026, its #935 holding.
  • Dimensional Fund Advisors first reported a position in Krystal Biotech in Q3 2019 and has held it in 25 quarters since.
  • Dimensional Fund Advisors's Krystal Biotech position peaked at $122M in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.